The global CRO where clinical trials run on time
Finding a CRO to deliver your pivotal Phase 2 & 3 clinical trials on time and on budget isn’t easy. Choose the CRO you can trust.
Therapeutic areas
Oncology
Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Ovarian Cancer and other Oncology indications.
Hematology
Multiple Myeloma, Lymphomas, Leukemias and other oncohematological indications.
Rare Diseases
Hemophilia A & B, Von Willebrand Disease, Thrombocytopenia, Polycythemia Vera, Paroxysmal Nocturnal Hemoglobinuria (PNH).
PSI On Point
The PSI Advantage
PSI CRO has been named a 2022 CRO Leadership Award Champion in the categories of Compatibility, Quality, and Reliability across two respondent groups (Overall and Small Pharma). This is also the fourth year in a row in which PSI CRO received CRO Leadership Awards in all five categories, also including Expertise and Capabilities. The CRO Leadership Awards are presented by Life Sciences Leader and Clinical Leader based on research conducted by ISR reports. The awards recognize CROs that are voted by sponsors to meet or exceed expectations.
Your last patient in is our first priority
PSI has been exceedingly professional and is respected by our site as a great collaborator.
Anthony W. Tolcher, MD, FRCP, FACP
Delivered 24 phase II and III IBD studies